In the next few minutes: what a GLP-1 hormone really is, how it changes appetite and blood sugar, what separates Ozempic from Wegovy from Mounjaro, how UK prescribing works, and the honest, unglamorous list of what these medicines actually can't do.
THE QUESTION — What actually is a GLP-1?
Everyone's talking about them. Ozempic, Wegovy, Mounjaro — jab pens, headlines, dinner party gossip. But strip away the noise and there's a simple question underneath: what actually is a GLP-1? Not a diet. Not a trend. A copy of a hormone your own gut already makes. Today, we go right back to basics — the hormone, the mechanism, the names, and the honest list of what these medicines can, and cannot, do.
THE HORMONE — Your gut already makes this
GLP-1 stands for glucagon-like peptide-1. It's not foreign. It's a hormone your own small intestine releases naturally, every time you eat. Its job, in the body's usual choreography, is to tell your pancreas and your brain that food has arrived. Scientists call this the incretin effect — gut hormones that boost insulin release after a meal, more than the same sugar given straight into a vein. GLP-1 medicines are simply a longer-lasting copy of that same signal.
THE TIMING — Released the moment you eat
Here's the catch with the natural version: it barely lasts. Your body breaks down its own GLP-1 within minutes of release — a burst of signal, then gone, chapter closed before the main course arrives. That's the entire engineering problem GLP-1 medicines were built to solve. Change the molecule's shape just enough, and it survives in the bloodstream for hours, sometimes an entire week, instead of minutes. Same message. Much longer broadcast.
THE VENOM — An unlikely origin story
The idea didn't start in a lab with diabetes in mind. It started with the Gila monster, a slow-moving desert lizard from the American southwest, whose venom contains a compound remarkably similar to human GLP-1. Researchers isolated it, called it exendin-4, and built the first GLP-1 medicine from that discovery. It reached patients in the mid-2000s, decades of chemistry later, as a twice-daily injection for type 2 diabetes, long before anyone was discussing weight loss.
THE ORIGINAL JOB — Built for blood sugar, first
For its first fifteen or so years on the market, this entire class of medicine had one job: helping people with type 2 diabetes manage blood sugar. Weight loss was noticed early, almost as a side effect worth watching, but it wasn't the headline. GPs prescribed it alongside metformin and other diabetes medicines, monitored by blood tests, adjusted over months. The weight-management version we hear about constantly now came later, and later still to the UK.
THE SLOWDOWN — Food stays in the stomach longer
Mechanically, GLP-1 medicines do several things at once. One is straightforward: they slow gastric emptying, meaning food sits in the stomach longer before moving through. Practically, that means the feeling of a full stomach lasts longer after a normal-sized meal. It's one reason portions that once felt small suddenly feel like plenty — not willpower, just digestion running at a different pace.
THE QUIET — Why appetite actually falls quiet
The second effect happens in the brain, not the stomach. GLP-1 receptors sit in the hypothalamus and brainstem, regions that regulate hunger and reward. The medicine's signal reduces what's sometimes called food noise — the background hum of thinking about the next meal, snack, or biscuit tin. Appetite doesn't vanish. It turns down. Many people describe it as simply forgetting to think about food as often.
THE SUGAR SIDE — Insulin, on demand, not on default
The original, diabetes-focused effect is about blood sugar control. GLP-1 prompts the pancreas to release insulin, but only when blood sugar is actually high — a built-in safety feature. At the same time, it dampens glucagon, a hormone that would otherwise push blood sugar up. Together, that combination smooths out the peaks and troughs that make type 2 diabetes harder to manage day to day.
ENTER GIP — A second gut hormone joins in
Not every medicine in this family works the same way. Some are GLP-1 alone. Others are dual-acting, adding a second gut hormone called GIP — glucose-dependent insulinotropic polypeptide, its own incretin with a similar job. Combining both signals in one molecule appears to produce a stronger effect on appetite and blood sugar than GLP-1 by itself, which is the entire reason the dual medicines exist and behave differently in practice.
ONE MOLECULE, TWO NAMES — Semaglutide wears two hats
Here's where the branding gets confusing. Semaglutide is the actual molecule name. Ozempic and Wegovy are both semaglutide — same active ingredient, made by the same company, but licensed in the UK for different purposes and different maximum doses. Ozempic is licensed for type 2 diabetes. Wegovy is licensed for weight management. Same hormone copy underneath, two separate jobs on the packet.
OZEMPIC — Licensed for type 2 diabetes
Ozempic's UK licence is for type 2 diabetes, prescribed to help manage blood sugar alongside diet and other medicines. Weight loss often happens as well, which is exactly why it became known outside diabetes circles in the first place. But its licensed purpose, the reason a GP would actually prescribe it, is blood sugar control — not weight loss as the primary aim.
WEGOVY — The weight-management version
Wegovy is the same semaglutide molecule, but licensed specifically for weight management in the UK, usually at a higher dose than Ozempic reaches. It's prescribed through weight-management pathways, not simply requested at a pharmacy counter. The distinction matters: it's not a stronger version of the same box, it's a different licence, for a different primary purpose, with its own prescribing route.
MOUNJARO — The dual-acting newcomer
Mounjaro's active ingredient is tirzepatide, the dual GLP-1 and GIP medicine mentioned earlier. In the UK it's licensed both for type 2 diabetes and for weight management, under one brand name covering both uses. Early trial data suggested a somewhat larger average effect on weight than semaglutide alone, though individual results vary considerably, and comparisons between trials are never perfectly like for like.
WHY THE NAMES SPLIT — Licence, dose and purpose, not marketing
Why bother with different brand names for the same or similar molecules? Because a medicine's UK licence is tied to its studied purpose, its tested dose range, and the safety monitoring built around that specific use. A diabetes licence and a weight-management licence are evaluated separately, even for identical chemistry. The name on the box tells a prescriber which pathway, which monitoring, and which patients it was actually tested for.
THE NHS ROUTE — How prescribing actually works here
In the UK, diabetes prescribing generally sits with your GP, as part of ongoing type 2 management. Weight-management prescribing typically runs through specialist services, commonly involving a BMI threshold alongside a weight-related health condition, plus support around diet and activity, not a jab handed over in isolation. Access, criteria and availability shift over time — the honest answer to 'am I eligible' is always a conversation with your GP or pharmacist, not a video.
WHAT THEY CAN DO — The evidence, stated plainly
So, the honest list. What they can do: consistently reduce appetite for most people who take them, support meaningful average weight loss in UK and international trials when combined with dietary changes, and improve blood sugar control for people with type 2 diabetes. These aren't marginal effects — trial data has been strong enough to genuinely change NHS and NICE guidance. That part is well established.
WHAT THEY CAN'T DO — The part nobody puts on a poster
What they can't do: replace the need for nutritious food. A quieter appetite still needs feeding well, because eating too little protein and fibre while appetite is suppressed can mean losing muscle along with fat, not just fat. They're not a guarantee — individual results vary widely. And they don't fix the food environment around you; the biscuit tin is still exactly where it was.
STOPPING AND STARTING — What commonly happens at each end
At the start, nausea is commonly reported, particularly as the body adjusts. At the other end, when someone stops taking a GLP-1 medicine, appetite commonly returns towards its previous level, and some weight regain is commonly reported too — because the underlying hunger signalling goes back to how it was before. Neither of these facts is a reason to panic; they're simply part of the honest picture.
WHO DECIDES — Your GP, your pharmacist, your call
None of this — eligibility, dosing, whether it's right for you — is a decision for a television programme, and it never will be. That conversation belongs with your GP or pharmacist, who know your history. What we can help with is the food side: eating well on or off any medication, checking sugar in what you actually reach for, and building meals that support whatever your body is doing. That part, we're genuinely useful for.
I've heard Mounjaro works better than Wegovy — is that true?
Trials suggest a somewhat larger average effect with tirzepatide, but individual results vary widely — that specific comparison is one for your GP, not a headline. (answer generated by SugarCoach, the AI coach)
General lifestyle education, not medical advice — personal medical decisions belong with your GP or pharmacist.